AR035798A1 - Compuestos inhibidores de aldosa reductasa del grupo de las piridazin-3-onas, composiciones farmaceuticas y metodos de tratamiento de isquemia y enfermedades diabeticas - Google Patents
Compuestos inhibidores de aldosa reductasa del grupo de las piridazin-3-onas, composiciones farmaceuticas y metodos de tratamiento de isquemia y enfermedades diabeticasInfo
- Publication number
- AR035798A1 AR035798A1 ARP020101134A ARP020101134A AR035798A1 AR 035798 A1 AR035798 A1 AR 035798A1 AR P020101134 A ARP020101134 A AR P020101134A AR P020101134 A ARP020101134 A AR P020101134A AR 035798 A1 AR035798 A1 AR 035798A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- substituents
- alkoxy
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos de piridazin-3-ona, a composiciones farmacéuticas que comprenden esos compuestos y a métodos de utilización de tales compuestos y composiciones para inhibir la aldosa reductasa, disminuir los niveles de sorbitol y, por tanto, hacer descender los niveles de fructosa, y/o tratar o prevenir complicaciones diabéticas tales como neuropatía diabética, retinopatía diabética, nefropatía diabética, cardiomiopatía diabética, microangiopatía diabética y macroangiopatía diabética, en los mamíferos. Se describen también métodos para proporcionar cardioprotección a sujetos no aquejados de diabetes. Se refiere también a composiciones farmacéuticas y a kits que comprenden una combinación de un inhibidor de la aldosa reductasa (ARI), y un inhibidor de la sorbitol deshidrogenasa, y a métodos de utilización de tales composiciones o kits para tratar o prevenir las complicaciones diabéticas anteriores en los mamíferos. Se refiere también a otras combinaciones con los ARIs de la presente, incluyendo combinaciones con agonistas de la adenosina, inhibidores de NHE-1, inhibidores de la glicógeno fosforilasa, inhibidores selectivos de la reabsorción de serotonina, agonistas del GABA, agentes antihipertensivos, inhibidores de la 3-hidroxi-3-metilglutaril coenzima A reductasa, e inhibidores de la fosfodiesterasa-5, y a agentes de disminución de la glucosa. Un compuesto de Fórmula (1), uno de sus profármacos o una sal farmacéuticamente aceptable de dicho compuesto o dicho profármaco, en la que: A es S, SO ó SO2; R1 y R2 son, cada uno independientemente, hidrógeno o metilo; R3 es Het1, -CHR4Het1 ó NR6R7; R4 es hidrógeno o alquilo C1-3; R6 es alquilo C1-6, arilo o Het2; R7 es Het3; Het1 es piridilo, pirimidilo, pirazinilo, piridazinilo, quinolilo, isoquinolilo, quinazolilo, quinoxalilo, ftalazinilo, cinolinilo, naftiridinilo, pteridinilo, pirazinopirazinilo, pirazinopiridazinilo, pirimidopiridazinilo, pirimidopirimidilo, piridopirimidilo, piridopirazinilo, piridopiridazinilo, pirrolilo, furanilo, tienilo, imidazolilo, oxazolilo, tiazolilo, pirazolilo, isoxazolilo, isotiazolilo, triazolilo, oxadiazolilo, tiadiazolilo, tetrazolilo, indolilo, benzofuranilo, benzotienilo, bencimidazolilo, benzoxazolilo, benzotiazolilo, indazolilo, bencisoxazolilo, bencisotiazolilo, pirrolopiridilo, furopiridilo, tienopiridilo, imidazolopiridilo, oxazolopiridilo, tiazolopiridilo, pirazolopiridilo, isoxazolopiridilo, isotiazolopiridilo, pirrolopirimidilo, furopirimidilo, tienopirimidilo, imidazolopirimidilo, oxazolopirimidilo, tiazolopirimidilo, pirazolopirimidilo, isoxazolopirimidilo, isotiazolopirimidilo, pirrolopirazinilo, furopirazinilo, tienopirazinilo, imidazolopirazinilo, oxazolopirazinilo, tiazolopirazinilo, pirazolopirazinilo, isoxazolopirazinilo, isotiazolopirazinilo, pirrolopiridazinilo, furopiridazinilo, tienopiridazinilo, imidazolopiridazinilo, oxazolopiridazinilo, tiazolopiridazinilo, pirazolopiridazinilo, isoxazolopiridazinilo o isotiazolopiridazinilo; Het1 está opcionalmente sustituido con hasta un total de cuatro sustituyentes seleccionados independientemente, cada uno de ellos, entre halo, formilo, alcoxi(C1-6)carbonilo, alquenil(C1-6)oxicarbonilo, alcoxi(C1-4)-alquilo (C1-4), C(OH)R12R13, alquil(C1-4)carbonilamido, cicloalquil(C3-7)carbonilamido, fenilcarbonilamido, bencilo, fenilo, naftilo, imidazolilo, piridilo, triazolilo, bencimidazolilo, oxazolilo, isoxazolilo, tiazolilo, oxadiazolilo, tiadiazolilo, tetrazolilo, tienilo, benzotiazolilo, pirrolilo, pirazolilo, quinolilo, isoquinolilo, benzoxazolilo, piridazinilo, piridiloxi, piridilsulfonilo, furanilo, fenoxi, tiofenoxi, alquil(C1-4)sulfenilo, alquil(C1-4)sulfonilo, cicloalquilo C3-7, alquilo C1-6 opcionalmente sustituido con hasta tres sustituyentes fluoro, o alcoxi C1-4 opcionalmente sustituido con hasta cinco sustituyentes fluoro; dichos bencilo, fenilo, naftilo, imidazolilo, piridilo, triazolilo, bencimidazolilo, oxazolilo, isoxazolilo, tiazolilo, oxadiazolilo, tiadiazolilo, tetrazolilo, tienilo, benzotiazolilo, pirrolilo, pirazolilo, quinolilo, isoquinolilo, benzoxazolilo, piridazinilo, piridiloxi, piridilsulfonilo, furanilo, fenoxi tiofenoxi, en la definición de sustituyentes para Het1 están opcionalmente sustituidos con hasta tres sustituyentes seleccionados independientemente entre hidroxi, halo, hidroxi-alquilo C1-4, alcoxi(C1-4)-alquilo(C1-4), alquil(C1-6)sulfenilo, alquil(C1-6)sulfinilo, alquil(C1-6)sulfonilo, alquilo C1-6 opcionalmente sustituido con hasta cinco sustituyentes fluoro y alcoxi C1-6 opcionalmente sustituido con hasta cinco sustituyentes fluoro; dichos imidazolilo, oxazolilo, isoxazolilo, tiazolilo y pirazolilo en la definición de sustituyentes para Het1 están opcionalmente sustituidos con hasta dos sustituyentes seleccionados independientemente entre hidroxi, halo, alquilo C1-4, hidroxi-alquilo C1-4, alcoxi(C1-4)-alquilo(C1-4), alquil(C1-4)-fenilo opcionalmente sustituido en la parte de fenilo con un Cl, Br, OMe, Me ó SO2-fenilo en el que dicho SO2-fenilo está opcionalmente sustituido en la parte de fenilo con un Cl, Br, OMe, Me, alquilo C1-4 opcionalmente sustituido con hasta cinco sustituyentes fluoro, o alcoxi C1-4 opcionalmente sustituido con hasta tres sustituyentes fluoro; R12 y R13 son, cada uno independientemente, hidrógeno o alquilo C1-4; Het2 y Het3 son, cada uno independientemente, imidazolilo, piridilo, triazolilo, bencimidazolilo, oxazolilo, isoxazolilo, tiazolilo, oxadiazolilo, tiadiazolilo, tetrazolilo, tienilo, benzotiazolilo, pirrolilo, pirazolilo, quinolilo, isoquinolilo, benzoxazolilo, piridazinilo, piridiloxi, piridilsulfonilo, furanilo, fenoxi y tiofenoxi; Het2 y Het3 están, cada uno independientemente, opcionalmente sustituido con hasta un total de cuatro sustituyentes seleccionados independientemente cada uno de ellos entre halo, formilo, alcoxi(C1-4)carbonilo, alquilenil(C1-6)oxi-carbonilo, alcoxi(C1-4)-alquilo(C1-4), C(OH)R18R19, alquil(C1-4)carbonilamido, cicloalquil(C3-7)carbonilamido, fenilcarbonilamido, fenilo, naftilo, imidazolilo, piridilo, triazolilo, bencimidazolilo, oxazolilo, isoxazolilo, tiazolilo, oxadiazolilo, tiadiazolilo, tetrazolilo, tienilo, benzotiazolilo, pirrolilo, pirazolilo, quinolilo, isoquinolilo, benzoxazolilo, piridazinilo, piridiloxi, piridilsulfonilo, furanilo, fenoxi, tiofenoxi, alquil(C1-4)sulfenilo, alquil(C1-4)sulfonilo, cicloalquilo C3-7, alquilo C1-4 opcionalmente sustituido con hasta tres sustituyentes fluoro o alcoxi C1-4 opcionalmente sustituido con hasta cinco sustituyentes fluoro; dichos fenilo, naftilo, imidazolilo, piridilo, triazolilo, bencimidazolilo, oxazolilo, isoxazolilo, tiazolilo, oxadiazolilo, tiadiazolilo, tetrazolilo, tienilo, benzotiazolilo, pirrolilo, pirazolilo, quinolilo, isoquinolilo, benzoxazolilo, piridazinilo, piridiloxi, piridilsulfonilo, furanilo, fenoxi, tiofenoxi, en la definición de sustituyentes para Het2 y Het3 están opcionalmente sustituidos con hasta tres sustituyentes seleccionados independientemente entre hidroxi, halo, hidroxi-alquilo C1-4, alcoxi(C1-4)-alquilo(C1-4), alquilo C1-4 opcionalmente sustituido con hasta cinco sustituyentes fluoro y alcoxi C1-4 opcionalmente sustituido con hasta cinco sustituyentes fluoro; dichos imidazolilo, oxazolilo, isoxazolilo, tiazolilo y pirazolilo en la definición de sustituyentes para Het2 y Het3 están opcionalmente sustituidos con hasta dos sustituyentes seleccionados independientemente entre hidroxi, halo, hidroxi-alquilo C1-4, alcoxi(C1-4)-alquilo(C1-4), alquilo C1-4 opcionalmente sustituido con hasta cinco sustituyentes fluoro y alcoxi C1-4 opcionalmente sustituido con hasta tres sustituyentes fluoro; y R18 y R19 son, cada uno independientemente, hidrógeno o alquilo C1-4; con tal que cuando R3 es NR6R7, entonces A es SO2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28005101P | 2001-03-30 | 2001-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035798A1 true AR035798A1 (es) | 2004-07-14 |
Family
ID=23071435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101134A AR035798A1 (es) | 2001-03-30 | 2002-03-27 | Compuestos inhibidores de aldosa reductasa del grupo de las piridazin-3-onas, composiciones farmaceuticas y metodos de tratamiento de isquemia y enfermedades diabeticas |
Country Status (44)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE41920E1 (en) | 1996-07-24 | 2010-11-09 | Warner-Lambert Company Llc | Isobutylgaba and its derivatives for the treatment of pain |
| ES2240657T3 (es) * | 2001-02-28 | 2005-10-16 | Pfizer Products Inc. | Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa. |
| AU2002226634B2 (en) * | 2001-03-30 | 2007-01-25 | Pfizer Products Inc. | Pyridazinone aldose reductase inhibitors |
| AU761191B2 (en) * | 2001-05-24 | 2003-05-29 | Pfizer Products Inc. | Therapies for tissue damage resulting from ischemia |
| PL371258A1 (en) | 2002-01-09 | 2005-06-13 | Pfizer Products Inc. | Process and intermediates for pyridazinone antidiabetic agents |
| US20040092522A1 (en) * | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
| US7419981B2 (en) * | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US6872833B2 (en) * | 2003-04-14 | 2005-03-29 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| EP1750862B1 (en) | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| WO2006028565A2 (en) * | 2004-06-30 | 2006-03-16 | Whitehead Institute For Biomedical Research | Novel methods for high-throughput genome-wide location analysis |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| MX2008009022A (es) * | 2006-01-13 | 2008-09-24 | Wyeth Corp | 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina. |
| ME00535B (me) | 2006-06-27 | 2011-10-10 | Takeda Pharmaceuticals Co | Fuzionisana ciklična jedinjenja |
| CN101663262B (zh) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物 |
| US8173645B2 (en) * | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
| WO2011071995A2 (en) | 2009-12-08 | 2011-06-16 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| TWI464147B (zh) * | 2011-09-15 | 2014-12-11 | Univ Taipei Medical | 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途 |
| US9339542B2 (en) * | 2013-04-16 | 2016-05-17 | John L Couvaras | Hypertension reducing composition |
| WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| CN103739547B (zh) * | 2014-01-03 | 2015-09-02 | 沈阳药科大学 | 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法 |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| EP3283074A4 (en) * | 2015-04-14 | 2018-12-05 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| CN115160339B (zh) | 2016-06-21 | 2024-05-14 | 纽约市哥伦比亚大学理事会 | 醛糖还原酶抑制剂及其使用方法 |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| US10344002B2 (en) | 2016-09-26 | 2019-07-09 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| EP3548035A4 (en) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | COMBINATIONS OF 15 PGDH INHIBITORS WITH CORTICOSTEROIDS AND / OR TNF INHIBITORS AND USES THEREOF |
| WO2018145080A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| MX2020001057A (es) | 2017-07-28 | 2020-11-24 | Applied Therapeutics Inc | Composiciones y metodos para tratar la galactosemia. |
| CN113574055A (zh) | 2019-01-18 | 2021-10-29 | 阿斯利康(瑞典)有限公司 | Pcsk9抑制剂及其使用方法 |
| JP2022534426A (ja) | 2019-05-31 | 2022-07-29 | イケナ オンコロジー， インコーポレイテッド | Ｔｅａｄ阻害剤およびその使用 |
| CN114502540A (zh) | 2019-05-31 | 2022-05-13 | 医肯纳肿瘤学公司 | Tead抑制剂和其用途 |
| WO2022120353A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE47592B1 (en) | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| US4939140A (en) | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| US4996204A (en) | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
| FR2647676A1 (fr) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
| WO1992009594A1 (en) * | 1990-11-30 | 1992-06-11 | Tsumura & Co. | Chromone derivative and aldose reductase inhibitor containing the same as active ingredient |
| BR9205810A (pt) | 1991-03-28 | 1994-06-28 | Pfizer | Acidos piridazinona acéticos |
| US5834466A (en) | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
| TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| AU735729B2 (en) * | 1997-09-24 | 2001-07-12 | Orion Corporation | Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors |
| FR2822827B1 (fr) * | 2001-03-28 | 2003-05-16 | Sanofi Synthelabo | Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant |
| AU2002226634B2 (en) * | 2001-03-30 | 2007-01-25 | Pfizer Products Inc. | Pyridazinone aldose reductase inhibitors |
| AU2002236131B2 (en) * | 2001-04-30 | 2005-04-14 | Pfizer Products Inc. | Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors |
| PL371258A1 (en) * | 2002-01-09 | 2005-06-13 | Pfizer Products Inc. | Process and intermediates for pyridazinone antidiabetic agents |
-
2002
- 2002-01-31 AU AU2002226634A patent/AU2002226634B2/en not_active Ceased
- 2002-01-31 PT PT02716247T patent/PT1373259E/pt unknown
- 2002-01-31 UA UA2003098846A patent/UA73236C2/uk unknown
- 2002-01-31 CA CA002442476A patent/CA2442476A1/en not_active Abandoned
- 2002-01-31 IL IL15646202A patent/IL156462A0/xx unknown
- 2002-01-31 PT PT04023149T patent/PT1491540E/pt unknown
- 2002-01-31 EP EP02716247A patent/EP1373259B1/en not_active Expired - Lifetime
- 2002-01-31 DK DK02716247T patent/DK1373259T3/da active
- 2002-01-31 JP JP2002577823A patent/JP2004528319A/ja active Pending
- 2002-01-31 BR BR0208571-2A patent/BR0208571A/pt not_active IP Right Cessation
- 2002-01-31 AT AT02716247T patent/ATE286049T1/de active
- 2002-01-31 EE EEP200300470A patent/EE200300470A/xx unknown
- 2002-01-31 CN CNB028076001A patent/CN1215067C/zh not_active Expired - Fee Related
- 2002-01-31 DK DK04023149T patent/DK1491540T3/da active
- 2002-01-31 EP EP04023149A patent/EP1491540B1/en not_active Expired - Lifetime
- 2002-01-31 EA EA200300673A patent/EA006023B1/ru not_active IP Right Cessation
- 2002-01-31 SK SK1185-2003A patent/SK11852003A3/sk unknown
- 2002-01-31 WO PCT/IB2002/000320 patent/WO2002079198A1/en active IP Right Grant
- 2002-01-31 ES ES04023149T patent/ES2274369T3/es not_active Expired - Lifetime
- 2002-01-31 OA OA1200300222A patent/OA12453A/en unknown
- 2002-01-31 AT AT04023149T patent/ATE348100T1/de not_active IP Right Cessation
- 2002-01-31 SI SI200230071T patent/SI1373259T1/xx unknown
- 2002-01-31 AT AT04023150T patent/ATE352551T1/de not_active IP Right Cessation
- 2002-01-31 NZ NZ528406A patent/NZ528406A/en unknown
- 2002-01-31 DE DE60217930T patent/DE60217930T2/de not_active Expired - Fee Related
- 2002-01-31 KR KR1020037012753A patent/KR100586138B1/ko not_active IP Right Cessation
- 2002-01-31 DE DE60216823T patent/DE60216823T2/de not_active Expired - Fee Related
- 2002-01-31 YU YU71403A patent/YU71403A/sh unknown
- 2002-01-31 ES ES02716247T patent/ES2231681T3/es not_active Expired - Lifetime
- 2002-01-31 MX MXPA03008850A patent/MXPA03008850A/es active IP Right Grant
- 2002-01-31 GE GE5314A patent/GEP20053675B/en unknown
- 2002-01-31 PL PL02365294A patent/PL365294A1/xx not_active Application Discontinuation
- 2002-01-31 EP EP04023150A patent/EP1491541B1/en not_active Expired - Lifetime
- 2002-01-31 DE DE60202452T patent/DE60202452C5/de not_active Expired - Fee Related
- 2002-01-31 HU HU0303644A patent/HUP0303644A3/hu unknown
- 2002-03-21 US US10/104,664 patent/US6579879B2/en not_active Expired - Fee Related
- 2002-03-22 PA PA20028541801A patent/PA8541801A1/es unknown
- 2002-03-27 AR ARP020101134A patent/AR035798A1/es unknown
- 2002-03-27 MY MYPI20021093A patent/MY134304A/en unknown
- 2002-03-27 UY UY27237A patent/UY27237A1/es not_active Application Discontinuation
- 2002-03-27 PE PE2002000246A patent/PE20030007A1/es not_active Application Discontinuation
- 2002-03-28 AP APAP/P/2002/002461A patent/AP2002002461A0/en unknown
- 2002-03-29 TN TNTNSN02037A patent/TNSN02037A1/fr unknown
- 2002-03-29 TW TW091106386A patent/TWI245762B/zh not_active IP Right Cessation
- 2002-03-31 CZ CZ20032563A patent/CZ20032563A3/cs unknown
-
2003
- 2003-02-20 US US10/370,895 patent/US6849629B2/en not_active Expired - Fee Related
- 2003-06-16 IS IS6845A patent/IS2205B/is unknown
- 2003-06-17 ZA ZA200304671A patent/ZA200304671B/en unknown
- 2003-06-25 EC EC2003004671A patent/ECSP034671A/es unknown
- 2003-09-17 MA MA27314A patent/MA27003A1/fr unknown
- 2003-09-17 HR HR20030752A patent/HRP20030752A2/hr not_active Application Discontinuation
- 2003-09-17 BG BG108179A patent/BG108179A/xx unknown
- 2003-09-29 NO NO20034345A patent/NO20034345L/no unknown
-
2004
- 2004-06-24 HK HK04104538A patent/HK1061678A1/xx not_active IP Right Cessation
-
2006
- 2006-01-23 IS IS8250A patent/IS8250A/is unknown
- 2006-01-23 IS IS8251A patent/IS8251A/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035798A1 (es) | Compuestos inhibidores de aldosa reductasa del grupo de las piridazin-3-onas, composiciones farmaceuticas y metodos de tratamiento de isquemia y enfermedades diabeticas | |
| EP3256463B1 (en) | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists | |
| ES2434946T3 (es) | Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo | |
| ES2385680T3 (es) | Derivados de quinazolinona 5 sustituidos como agentes antitumorales | |
| ES2601131T3 (es) | Derivados de isoindolina 4'-O-sustituidos y composiciones que los comprenden y métodos de uso de los mismos | |
| US9932326B2 (en) | Potent and selective inhibitors of hepatitis C virus | |
| ES2736450T3 (es) | Compuestos de isoindolina 5-sustituida | |
| ES2289161T3 (es) | Derivados de 4-(heteroaril de 6 miembros)-acil pirrolidina como inhibidores de hcv. | |
| ES2345044T3 (es) | 2-piperazin-piridinas utiles para tratar el dolor. | |
| ES2327684T3 (es) | Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor. | |
| ES2697607T3 (es) | Compuestos sustituidos de piridinon-piridinilo | |
| CN110573154A (zh) | 调节短链脱氢酶活性的组合物和方法 | |
| US20120251491A1 (en) | Fused tricyclic aryl compounds useful for the treatment of viral diseases | |
| US20120258078A1 (en) | Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis c | |
| US20080214615A1 (en) | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | |
| CA2458471A1 (en) | Prostaglandin analogs as chloride channel opener | |
| JP2018511616A (ja) | 短鎖デヒドロゲナーゼ活性を調節する組成物および方法 | |
| WO2010138790A1 (en) | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c | |
| BRPI0510591A (pt) | compostos benzilideno-beta-dicarbonila como novos filtros de uv | |
| JP2004528319A5 (es) | ||
| PE20091425A1 (es) | Derivados de aminotiazol | |
| KR102270620B1 (ko) | 섬유아세포 성장 인자 수용체의 억제제 및 이의 용도 | |
| KR20090109102A (ko) | 바이러스 감염의 치료를 위한 신규 뉴클레오시드 유사체 | |
| WO2008151460A3 (en) | Cooling compounds | |
| WO2015169180A1 (en) | Substituted piperazine compounds and methods and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |